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Abstract Unprecedented progress in sequencing technolo-
gies and decreasing cost have brought genomic testing into
the clinical setting. At the same time, the debate in the litera-
ture concerning the return of incidental findings (IFs) has
made this an important issue internationally. These develop-
ments reflect a shift in genetics that will also affect smaller
countries, such as Greece, that are just starting to implement
these technologies and may look to other countries for exam-
ples of good practice. Ten in-depth interviews were conducted
with Greek experts in clinical sequencing. Previous experi-
ences and attitudes toward IFs and clinical sequencing were
investigated as well as views on the existing policy regarding
managing genetic information generated through testing. .
Interviews were analysed using thematic analysis. All partic-
ipants reported the lack of any legal or other supportive
mechanism. IFs are currently managed at a “local” level, i.e.
within the clinic or the laboratory in an ad hoc way. All
participants thought that clinically valid and actionable IFs
should be returned, but always with caution and in respect to
patients’ wishes, although several experts reported returning
IFs according to their clinical discretion. Experts reported that
most patients ask for all tests available but they felt that more
counselling is needed to understand and manage genetic in-
formation. Due to the lack of any supporting mechanisms,
professionals in Greece, even those with established experi-
ence in the field of genetic and genomic testing, have difficul-
ties dealing with IFs. All experts agreed that it is now time,
before the full integration of genomic testing into everyday
clinical practice, for guidance to help Greek physicians work
with patients and their families when IFs are discovered.
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Introduction
The development of whole-exome and whole-genome tech-
nologies (next generation sequencing (NGS)) has been revo-
lutionary, and their use as a diagnostic tool in clinical sequenc-
ing has transformed everyday clinical practice. With costs
expected to fall to $1,000 per genome (Check Hayden
2014) and the continuing development of software to facilitate
data interpretation, the integration of NGS into the clinical
setting (Lyon et al. 2011) is moving very quickly. This means
there has been limited time available for public dialogue
regarding its potential implications. One of the main issues
coming out of the use of NGS is the increased possibility of
discovering incidental findings. Incidental findings (IFs) have
been defined as findings with potential health or reproductive
importance to individuals discovered during diagnostic testing
or during research but falling outside the diagnostic indication
for which the test was ordered (Wolf et al. 2008). A recent
publication (March 2014) from the Medical Research Council
(MRC) and the Wellcome Trust in the UK provides a clearer
framework about IFs from research settings (MRC and
Wellcome Trust 2014) and reflects the ongoing effort to
provide clear guidance.
IFs in the clinical setting first appeared in relation to imag-
ing tests (Morris et al. 2009; Lumbreras et al. 2010), and the
phenomenon quickly spread into genetic and genomic test-
ings. Until recently, little guidance was available regarding
how IFs from clinical genomic testing are to be dealt with.
Available recommendations concern mainly return of IFs
from research (Cassa et al. 2012) and have been criticised
as inconclusive (Zawati and Knoppers 2012; Knoppers et al.
2013; Lawrenz and Sobotka 2008).
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The most specific guidelines about IFs from the clinical
setting currently available are from the American College of
Medical Genetics and Genomics (ACMG) published in 2013
(Green et al. 2013). ACMG recommends that when
conducting clinical sequencing, regardless of the diagnostic
indication for which the test is being conducted, or the age of
the patient, laboratories should actively look for and report
mutations on listed genes. The variants included in the list
were medically actionable and concerned conditions with
well-established genetic aetiology. Although these recommen-
dations were revised on April 2014 (ACMG 2014) allowing
patients to opt out from receiving IFs, they still represent the
beginning of a discussion that has dominated the literature for
the last 15 months.
Additional guidance comes from the Presidential
Commission for the Study of Bioethics Issues (USA). In their
report published in December 2013, they recommended that
regardless the setting “practitioners should inform potential
recipients about the possibility of incidental findings” and
ascertain recipients’ intentions about receiving them ahead
of time (BioethicsGov 2013). At a European level, the
European Society of Human Genetics in their “Call for
Prudence” encourage the use of targeted tests to avoid IFs,
while acknowledging that “patient’s right not to know may
sometimes have to be secondary to clinical geneticists’ pro-
fessional responsibilities” (van El et al. 2013a, b).
These recommendations and the discussion surrounding
ACMG recommendations (Green et al. 2013; Couzin-
Frankel 2013; Klitzman et al. 2013; McGuire et al. 2013;
Bombard et al. 2013; Ross et al. 2013) and their early
adoption (GenomeWeb 2013; Heger 2013) highlight the fact
that this field is moving very quickly and brings to the surface
fundamental differences in ethical views. Experts from the
USA and Europe have expressed their reservations about the
implementation of the ACMG recommendations suggesting
that more evidence is needed and that these recommendations
might not be appropriate for all types of clinical sequencing
(Middleton et al. 2014; Burke et al. 2013; Hickner 2013).
These guidelines could seem attractive for adoption by
smaller counties where there are currently no guidelines and
where resources are limited to produce guidelines by them-
selves, such as in the case of Greece. However, to ensure what
guidelines are appropriate for each country, various stake-
holders need to be approached. Given the controversy, it is
crucial to ascertain the attitudes of different stakeholders.
These stakeholders are likely to include, among others, pro-
fessionals and experts in genomics, patients, and the lay
public. Input from different countries should also be sought
to compare and contrast different attitudes. These perspectives
could then be used to support the creation of guidelines in
other countries that would better reflect cultural differences.
Our aim in this paper is to describe the existing situation in
Greece and report the first study investigating Greek experts’
attitudes toward return of IFs from clinical sequencing. We
believe that the input from Greece could add to the broad
literature and encourage an international dialogue between
countries with strong traditions in governance of genetic test-
ing and other countries, such as Greece, that are just beginning
to apply these technologies and are looking to other countries
for examples of public health policies.
The Greek context
Currently in Greece, patients have access to genetic testing
through both the public and the private sectors. An individual
with a diagnostic indication or family history for a genetic
condition can consult a physician who will refer the individual
to a specialised clinic or one of the available genetic labora-
tories. Most of the public laboratories are linked to a university
hospital. Such laboratories can be found in some of the major
cities in Greece, such as Athens, Thessaloniki, Patra, and
Ioannina. In the public sector, it is currently unclear which,
if any, of the costs will be covered by health insurance.
Alternatively, an individual can go directly to one of many
private laboratories, located in most cities in Greece, and ask
for any available genetic test (Intergenetics 2014). The cost of
the test will need to be paid by the individual unless he or she
has private insurance willing to cover some of the expenses.
In 2013, the Hellenic Association of Medical Genetics
(HAMG) and the Hellenic Society of Medical Genetics
(HSMG 2011), the two professional association of its type in
Greece, had 240 registered members. These included clini-
cians, dentists, biologists, and biochemists working in genet-
ics (HAMG 2013: content in Greek). No genetics-related
medical specialty is recognised by the state. More specifically,
neither the specialty of clinical geneticist nor the specialty of
lab-based geneticist is recognised. Professionals working in
genetic and genomic testing have gained their expertise either
abroad, where such specialist training is available, or through
working in this area for many years. There is also no specialist
training for or a recognised speciality of genetic counselling.
This role is taken on by clinicians and geneticists who provide
this service as a part of their clinical relationship with their
patient.
Genetic testing in Greece is regulated by the legal frame-
work that applies to health services as a whole. The ability of
users to access genetic services is regulated to protect patient
rights. According to law number 2472/1997 concerning the
use of personal data (Greek Government 1997), all health-
related data are considered “sensitive” and can therefore be
collected, stored, or processed only by the Hellenic Data
Protection Authority and only after the individual’s informed
consent. An exception can be made if the processing concerns
health data and is conducted by a person who is, by training,
working in health services and is bound by confidentiality and
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deontological codes of practice. The processing must also be
necessary for clinical services, such as medical prevention,
diagnosis, nursing, or the management of health services.
Any institutional guidance on sharing personal data be-
tween doctors and their patients reflects international codes
of practice such as UNESCO’s Universal Declaration on the
Human Genome and Human Rights (1997) (UNESCO 1997)
and International Declaration on Human Genetic Data (2003)
(UNESCO 2003). These declarations seek to provide guid-
ance for best practice in the protection of patient data deriving
from genetic tests. Additionally, the Oviedo convention,
which only addresses the return of findings from research, is
integrated into Greek legislation with law number 2619/1998
(Greek Government 1998), and states that “everyone is enti-
tled to know any information collected about his or her health.
However, the wishes of individuals not to be informed shall
also be respected”.
One of the reasons there is no guidance for clinicians in
Greece is because there are no organisations formally respon-
sible for the creation of good practice guidelines. Clinicians
rely on the law concerningMedical Ethics (number 3418/2005)
(Greek Government 2005) for general guidance regarding their
duties toward patients and their families. According to this law,
physicians are responsible for developing a relationship of
mutual trust with their patient and respecting his or her wishes
and beliefs. The physician bears a “duty of truth” toward the
patient. The patient should be fully and comprehensibly in-
formed and should have understood the risks of the test. The
physician shall respect an individual’s wish not to be informed.
In this case, the patient has the right to ask the physician to
exclusively inform another or other people of the patients about
their condition and the results of medical investigations. The
physician shall not disclose confidential information to anyone
unless the patient has requested otherwise.
There is a need for more specific guidance regarding ge-
netic testing and return of results. This issue is important and
will becomemore so with the increasing integration of genetic
testing into clinical practice and the use of less targeted genetic
testing that might produce more results of unknown signifi-
cance. It remains unclear what form this guidance could best
take; it may be in the form of a law or a set of guidelines or
recommendations by a professional organisation, which could
be sufficient for the transitional period until genomic testing is
fully integrated in the clinical setting.
Our goal is to investigate experts’ attitudes toward clinical
sequencing and return of IFs in order to help us gain a better
understanding of the current situation in Greece.
Methods
Ten in-depth interviews were conducted with Greek experts
acting as key informants. We have defined experts as
clinicians, geneticists and professionals with a bioethical
background with experience of clinical sequencing. The num-
ber of professionals in Greece with extensive experience in
genomic testing is limited. However, the sample, while not
typical of the general population, is considered as typical of
Greek experts in genomic testing.
Given that there are no official records of genetic/genomic
professionals in Greece, professionals were invited according
to their experience, as evidenced through their published work
on genomic testing and conference presentations in Greece.
There have been no publications about IFs in clinical sequenc-
ing in Greece or about the issue in the Greek language. Four
experts were initially identified, and additional professionals
were recruited using a snowballing technique (Wimmer and
Dominick 2011).
In total, 20 experts working with genetic and genomic
testings in either the public or the private sector were
invited to participate via email. Fifteen experts responded,
of whom five did not regard themselves as sufficiently
experienced or currently working in a relevant area. The
remaining ten agreed to be interviewed and an email was
sent to arrange a meeting at a time and place of their
convenience. All participants received an information
leaflet and signed a consent form at the beginning of their
interview. Interviews were performed in interviewees’
preferred language. All interviews were conducted by
EGG. This study was approved by the University of
Leicester College of Medicine and Biological Sciences
Ethics Committee.
A draft topic guide was used to facilitate discussion and
ensure that all topics of interest were covered. In addition to
this topic guide, a vignette, describing a scenario where an IF
is discovered in a cancer patient using NGS to receive
personalised treatment, was used in all interviews to facilitate
the discussion process and provide a point of continuity across
interviews.
With participants’ consent, interviews were recorded and
transcribed into both Greek and English. Transcripts were
analysed using thematic analysis as described by Braun and
Clarke (2006). Initial codes were generated, and then, themes
were identified, defined and named. An initial coding frame
was generated from the research questions which acted to
guide, but not constrain, the analysis. Interviews were coded
using NVivo, and themes and sub-themes were developed and
iteratively revised.
Three clinicians, two experts with bioethical background
and five geneticists, four of whom also wore the “hat” of a
genetic counsellor, were interviewed. Given the small number
of professionals working in this area in Greece, we have
chosen not to give job titles and/or roles when presenting the
results below due to the risk of unintentionally revealing
participants’ identities. Instead, we use simple numbers to
tag each quotation.
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Results
Why IFs from clinical sequencing are challenging
Our experts considered that NGS should be considered as “the
last resort” and should therefore be ordered only when all
other tests have failed to give a diagnosis. Clinicians especial-
ly reported that they are trying not to generate IFs by selecting
targeted sequencing rather than NGS and by keeping NGS as
the “last resort”. Clinicians believed that using NGS in the
clinical setting would create problems because “if you start
looking, you will definitely find something”. Therefore, for
the time being, targeted sequencing would be more useful.
For me it is rather simple. If symptoms resemble
Huntington’s for example I will order a test only for
that. I won’t start looking around. I won’t even use
genetic testing unless I have to. I am not saying that it
is not useful, because it is, and occasionally we have
managed to diagnose conditions that we couldn’t have
done otherwise, but if I can use other kinds of testing I
would rather do that. With genetic testing you never
know what you will get (Participant 10).
Not even for cancer. If later we discover that all cancers
are hereditary maybe then but until then I would only use
genomic testing rarely in extreme cases (Participant 04).
Although Greek experts noted that there are some similar-
ities with other areas of medical practice that can provide a
starting point, clinicians reported that the concept of IFs is
well integrated in the medical philosophy and they have been
“taught” how to handle them during their medical training.
But IFs are not something you could only have in
genetic testing. We always knew that could happen
(Participant 04).
Most tests could give you IFs. We have been trained and
we always knew that the more you look the more you
will find. It might be even more with genetic testing but
the idea is the same (Participant 10).
Additionally, they all reported having experience of han-
dling IFs from other types of genetic testing and thought this
would be of some help when dealing with IFs deriving from
NGS testing.
We have been thinking about this for a long time now.
Especially with arrays [array-CGH (Comparative Ge-
nomic Hybridization)] we have found unexpected things
more than once. It’s not something new (Participant 05).
Oh, yes. We are used to having IFs. We have them in
prenatal testing very often. Ever since we started using
the classical karyotype. You are looking for one thing
and you find something else. Now we are going to use
all this experience for clinical sequencing. This is not
new to us (Participant 07).
Previous experience from other types of testing could
inform practices about IFs from clinical sequencing (e.g. IFs
discovered during prenatal tests using cytogenetic tests); yet,
experts considered that IFs differ in important ways. First, all
participants reported that a very important difference was that
genetic information affects more than just the actual patient or
the person getting tested. The nature of genetic information
makes it unique and complex because it is shared by all family
members, even those not affected by the genetic condition in
question.
What is different this time is that family members have
even a legal right to have access to that information.
Because it could affect them too (Participant 01).
Learning any genetic information is something you
should share. It doesn’t affect only you. People need to
overcome their spontaneous reaction of hiding some-
thing that is bad and share it. This might make a
difference in other people’s lives. They might have the
opportunity to get tested, follow up even have a treat-
ment. It is a moral obligation (Participant 03).
A second important factor that was acknowledged by most
participants was that this is an area in which knowledge and
scientific understanding is constantly developing. This needs
to be taken into account when making choices about the
results that should be returned.
The problem with genetics is that we think we know
something today and then in a year’s time it is proven
wrong or insufficient. We can’t pretend we know every-
thing because we don’t (Participant 02).
Because everything changes so quickly we might
have to consider keeping findings and returning them
on a later time if we are not sure what they mean now
(Participant 05).
Third, there was a consensus among all experts that when
using clinical sequencing, especially NGS, it is the interpreta-
tion of the results that is important, not the test itself.
Anyone could buy the equipment for NGS but there are
only a few who could interpret results. And there is the
whole importance. Because we will get so many results,
we will have a look and using specific software we will
throw 1998 or 1999 out of 2000. The remaining ones we
will see. We will have to think about them and consider
the family as well (Participant 08).
Fourth, clinicians in particular also suggested that genetic
conditions differ in another important way: most genetic con-
ditions are not actionable. For some conditions the only
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“action” that could be taken would be the option of prenatal or
preimplantation diagnosis, if available, as no preventive mea-
sures were available.
The problem is that for most genetic conditions there
is nothing you can do! Only be informed, follow-up
and help other make reproductive choices if you can
(Participant 04).
A patient with a hereditary genetic condition comes very
close to his doctor. It’s not like having a respiratory
condition that he could take two sprays [respiratory
drug] and get well. Here you have many issues, social,
psychological, moral (Participant 10).
Fifth, returning genetic information to patients differs
from returning other health-related information because
learning genetic information has the potential to change
someone’s life, especially if it is unexpected and seri-
ous. Many participants suggested that when conveying
“bad news”, the support of a clinical psychologist would
be vital.
Especially if what you are going to tell them is really
bad you need there a psychologist. They will know better
how to help them (Participant 05).
We had a psychologist at some point as a member of
our group when disclosing such information. And
that made a great difference. Because these people
need support in more than one way and long-term
support (Participant 10).
Finally, particularly in the Greek context, genetic
information might have another special characteristic.
Participants stated that Greek society remains relatively
traditional in certain domains. The experts interviewed
suggested that being diagnosed with a genetic condition
could lead to stigmatisation. This could discourage fam-
ilies, especially parents, from disclosing a genetic diag-
nosis even to their children. In this way, children are
being deprived of the opportunity to follow up and
make relevant reproductive choices.
We are having mothers of teenagers or young adults
coming here and they say “… how would we manage to
find her a husband if people would know that we have
that?” and they don’t tell them anything. And then their
kids grow up and have kids of their own and they don’t
have the chance to use prenatal or pre-implantation
diagnosis and they end up having kids with serious
juvenile form of these conditions and when they learn
that they could have known and could have done some-
thing about it they so disappointed. They would do
everything to avoid being stigmatised. We face that very
often here [in Greece] (Participant 10).
How IFs are currently returned
Regardless of the concerns expressed, clinicians order
less targeted sequencing and IFs are being generated.
Currently, when IFs are discovered, they are managed at
a “local” level, i.e. within the clinic or the laboratory,
on an ad hoc basis. Clinicians and geneticists reported
that they meet together and discuss cases as they arise.
Results, including any IFs, are then discussed between
the ordering clinician, a geneticist and a genetic coun-
sellor (if there is one available), or a team consisting of
clinicians and geneticists.
For the time being we are working all together. Clini-
cians bring the geneticists and with help from the social
service of the hospital we make a decision. The social
service has helped us quite a lot. But not all hospitals
have one! (Participant 10)
If something like that would happen the only thing we
can do is to discuss it all together, there is nothing else
(Participant 03).
All results, both diagnosis-related and IFs, are given to
patients during a genetic counselling session where the clini-
cian or the geneticist is acting as a genetic counsellor. The
results are being returned orally and also in writing.
Here we are also acting as genetic counsellors as well.
There is no one else to disclose results. Physicians
neither can nor want to do it. They know they are not
trained for it, and neither are we but since there is no-
one else, we have to (Participant 08).
We give results during genetic counselling but we also
hand them a report to have it for their personal medical
record (Participant 03).
Although this was the current practice reported, experts
expressed differing views on who should return results.
All experts underscored the importance of having a per-
son who is properly trained for this task but their defini-
tions of “properly” differed. Clinicians believed that they
were the most appropriate group, while geneticists and
experts with a bioethical background thought that results
should be disclosed by a multidisciplinary team. This
team should consist of not only clinicians but also other
professionals, such as geneticists and clinicians
specialised in the relevant condition (e.g. oncologist if a
cancer susceptibility gene had been discovered). At the
same time, most of the experts questioned the appropri-
ateness of clinicians not specialised in genetics dealing
with genetic tests and the results, especially when NGS is
used. They were of the opinion that non-specialist clini-
cians lacked the expertise to explain the procedures and to
provide pre- and post-testing counselling. The lack of a
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recognised specialty of “clinical geneticist” made things
even harder.
To understand that, here we are acting as genetic coun-
sellors because we don’t have genetic counsellors and
doctors don’t know what to do. They are asking for our
help and sometimes even we don’t know what to do
(Participant 05).
Not to mention that we don’t even have a specialty
recognised! (Participant 02)
Which results should be returned?
Most experts mentioned the concept of “patient autonomy”
and understood this as each patient’s individual right to choose
whether or not to be told about IFs, although their ideas about
the best way to achieve this varied.
We need to make sure that they are informed well
enough and that they are deciding autonomously. We
should give them all the information we can and let them
decide by themselves (Participant 03).
Whoever is doing the genetic counselling should
provide all the available information. They should
let them know that IFs could be discovered. And
then it is on the individual’s responsibility to ask his
doctor if they indeed discovered something. This way we
would be sure that the individual actually wants to learn
the findings. If it is the doctor that asks then that is not
exactly autonomous! They need to actively participate!
(Participant 01)
However, it seems current practice is not always guid-
ed by this principle. Clinicians admitted they do occa-
sionally adopt a more paternalistic approach and try to
act in what they think is their patient’s best interest, even
if this means making some preliminary decisions by
themselves.
Even if the patient has asked for all results we won’t give
him everything. We will definitely give him clinically
valid and clinically actionable ones, or results that
concern serious of life-threatening conditions but about
the rest of them… I don’t know. We will discuss about it
and according to what we will decide we will let him
know (Participant 06).
We won’t give him everything. We will discuss it and we
will decide what he needs to know (Participant 08).
Importantly, most experts believed that patients and
their families, who may be asking for all available
information to be returned, are not in a position to deal
with genetic results and will have even greater difficulty
understanding results that are unexpected and unrelated
to the original diagnosis.
They [patients] want to know as much information as
they can. Few are those saying that they don’t want to
know. If they could afford it they would want to do every
kind of test they could! But they have a hard time when
you actually get back at them with results. They don’t
know what to do with it, especially with multi-factorial
conditions (Participant 06).
In Greece yes! They want to know everything. They ask
for everything. And they want us to test them for all
available genes.
(Interviewer: And do you think they are handling these
results?)
No, no way. They definitely cannot! They don’t really
know what they ask for (Participant 04)
Experts believed that the only way to support these families
was by spending a considerable amount of time with them
giving pre-testing counselling where they try to explain ev-
erything according to the patient’s needs and level of
understanding.
How much they [patients] can understand is related to
how much time you spend with them and how patient
you are. According to the literature we are supposed to
have a one-and-a half-hour counselling session. And we
are doing that here. Our slogan is that you won’t leave
unless you understand! (Participant 10)
Therefore, notwithstanding their awareness of the patient’s
right to choose, all participants had their own ideas about
which results should be returned and when. All believed that
clinically valid and actionable results should be returned.
Interestingly, not all of them seemed to think about
“actionability” in the same way. Some saw actionable as
meaning only results that could lead to treatment, while others
also included results that could provide other family members
with the opportunity to make different reproductive choices
even if no intervention was available.
Only if there is a treatment available. If there is none
then what’s the point of telling them? (Participant 01)
If there is something they could do about it then yes. […]
if they want to have a child they should know to be able
to use prenatal or preimplantation testing to try to avoid
that condition (Participant 04).
Regarding returning IFs to minors, experts stated that re-
sults should be returned in cases where there could be an
impact on patients’ reproductive choices or when there would
be an opportunity to follow up or have access to preventive
measures for minors in the future. Several experts expressed
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their concern regarding IFs about late-onset conditions, be-
lieving that such findings could cause more harm than good.
Clinicians were slightly less willing to disclose results com-
pared to geneticists.
Let’s say you find Huntington’s in a 5-year old boy, that
is a finding you can’t neglect. But what is the point of
returning a result about something that will happen
40 years later? There is a huge one! Science is evolving
so quickly and that kid could be able to do something to
delay the symptoms or participate in a clinical trial
much sooner (Participant 10).
Forme to inform someone for something that will happen
20–30 years later doesn’t make sense. You force him to
“medicalise” his life. I don’t think he needs to know. Not
for something that will happen that far away. Especially
if there is nothing he can do about it. He could learn
about it later. I prefer to inform them for something that
will happen in the near future (Participant 01).
There were differing opinions about results that are clini-
cally valid but not clinically actionable. Clinicians were less
willing to return them than geneticists or professionals with a
bioethical background, but they did all agree that they would
like to know their patient’s wishes in advance. As above, the
importance of pre- and post-testing counselling was
underlined by all experts in these cases and all agreed that if
a patient had consented to receive results, then, his or her
wishes should be respected.
What needs to change in Greece?
As discussed earlier, currently, there is no framework to guide
practice in Greece. All experts noted the lack of any legal
documents, guidelines or other supportive mechanism to sup-
port clinicians, geneticists or the laboratories using sequencing
technologies if IFs are discovered.
There is nothing. Absolutely nothing! No supportive
mechanism, no laws. Nothing! Every laboratory has,
in best case scenario, done what we have done. We have
an ad hoc process to solve problems like that. We all
meet [clinicians, geneticists] and discuss case by case
(Participant 04).
Many experts expressed their disappointment about the
current situation in Greece and their belief that things would
not change easily. Two key things are needed, according to
those interviewed: better public understanding and clear
guidelines to support professionals.
Lay people should be educated about genetics. Because
in Greece we have many genetic conditions. In certain
areas because of inbreeding the prevalence of genetic
conditions is huge. People should learn about it. And
they should also learn about the nature of genetic infor-
mation. And we need studies reporting the frequency of
genetic conditions in Greece (Participant 10).
We should have a consensus among stakeholders,
clinicians, professionals’ associations, geneticists. And
all of them should describe a process, step-by-step the
counselling process, something like guidelines and a
leaflet that could be distributed to lay people before
using clinical sequencing (Participant 07).
When asked if they would like to have a list of conditions
for which IFs should be returned, such as the list prepared by
ACMG in the USA, the majority stated that because a list
could never be complete, it would be better to have guidelines
describing the criteria, rather than the conditions, for which
IFs should be returned.
We need a committee to prepare a catalogue, a list with
all the necessary rules. You can’t describe all conditions
(Participant 05).
We need a list with the criteria not a list of genetic
conditions. Guidelines for all laboratories describing
what results should be returned, in what age, the sever-
ity of condition, what would happen with late-onset,
with minors …things like that (Participant 06).
Finally, many suggested that we do not need to “re-invent
the wheel” but we could instead look to what was available in
other countries and adapt it to the Greek context.
I would like to have some short of soft-law, i.e. guidelines
from a professional association that would describe
what is happening in other countries, what is the state
of the art abroad. And from that they could bring some-
thing and adapt it according to our need here. We don’t
need to start from the beginning when there could be
something available abroad (Participant 09).
Discussion
Our goal was to investigate Greek experts’ attitudes toward
clinical sequencing and return of IFs. Their extensive experi-
ence and expertise was used to help us acquire a better
understanding of the existing situation in Greece regarding
clinical sequencing and the return of IFs.
From the interviews, a consensus could be observed among
experts from different backgrounds that IFs that are clinically
valid and actionable should be returned, always according to
patients’ wishes. In the same way, they all acknowledged the
importance of pre- and post-test counselling and the fact that
J Community Genet (2014) 5:383–393 389
when it comes to NGS testing, interpretation of results is the
area requiring the most attention. Most experts agreed that IFs
discovered in minors should be returned in most of the cases
but with extra caution. Finally, they all insisted on the need to
have guidelines as soon as possible but preferred a list with
criteria and detailed counselling advice rather than simply a list
of genetic conditions they would be required to search for and
if found, about which they would need to inform their patients.
On the other hand, no consensus could be found regarding
what actions should be taken regarding clinically valid but
non-actionable results and the best time to return IFs. Several
differences were observed between clinicians and geneticists.
Clinicians preferred more targeted genetic testing while ge-
neticists were more willing to use NGS. Additionally, clini-
cians were less in favour of returning non-actionable results
and informing a patient’s family of them.
Greek experts seemed to consider that genetic testing, and
the genetic information derived from it, differs in some im-
portant ways from other medical information, as this data
concerns family members apart from the patient and scientific
knowledge and understanding change very quickly in this
context. Additionally, the meaning of actionability was also
raised by many and understood in more than one way. Patient
autonomy was referred to as an ideal, but problems with
managing this in practice were highlighted.
Our findings are in agreement with studies conducted else-
where, both from clinical settings and research, and suggest
that a consensus exists only regarding IFs that are both clini-
cally valid and actionable (Downing et al. 2013; Facio et al.
2011, 2013; Lohn et al. 2013; Brandt et al. 2013; Green et al.
2012; Lemke et al. 2012; Townsend et al. 2012; Dimmock
2012). Theoretical and more philosophical approaches have
also suggested that, at least for the time being, only these
should be disclosed (Berg et al. 2011; Goddard et al. 2013;
McGuire et al. 2008). The same is true for results from genetic
research in general (Abdul-Karim et al. 2013), research using
NGS (Klitzman et al. 2013) or research involving biobanks
(Goldman et al. 2008; Meulenkamp et al. 2012).
The importance of pre- and post-test counselling and the
need to provide individual support depending on patients’
needs and understandings was also mentioned. As suggested
elsewhere (Middleton et al. 2007), depending on their needs,
patients develop different relationships with their clinicians or
genetic counsellors so the patient’s preferences should be
taken into consideration. The use of NGS would require very
long counselling sessions, over 5 h, making it impractical and
with questionable utility for patients (Ormond et al. 2010). As
our experts suggested, spending time with patients would
make a difference; it might be worth considering that alterna-
tives are needed to support patients with other ways apart from
prolonging the counselling session. Finding the right balance
between providing enough information to help a patient to
make an informed decision and providing too information that
it becomes “counterproductive” (Ormond et al. 2010) is
another challenge that needs to be faced before the full inte-
gration of NGS in the clinical setting.
Greek experts seemed particularly concerned about poten-
tial stigmatisation, noting that Greek society might be more
traditional than others and individuals might feel discouraged
to disclose genetic information even within the family.
Although potential discrimination and stigmatisation have
been discussed in other studies about receiving results from
clinical sequencing (Downing et al. 2013; Townsend et al.
2012), or participating in research (Halverson and Ross 2012),
concerns about disclosure within a family are rarely men-
tioned (Clarke et al. 2005; Wilson et al. 2004). Our clinicians
suggested that parents might not feed back results to their
children or anyone else in their family, because they are afraid
that their offspring might have difficulties in getting married if
associated with a diagnosed genetic condition. This finding is
also discussed among BRCA carriers (Dimillo et al. 2013) or
patients with neurodegenerative diseases (Paulsen et al.
2013). Usually, stigmatisation and potential discrimination
are discussed in relation to mental health conditions (Yang
et al. 2013) or in regard to health insurance (Kass et al. 2007)
but has not actively been discussed in the context of IFs.
The Greek experts interviewed would prefer to decide
which results to feed back according to their clinical discre-
tion, and they stated that, for the time being, this should be
done on a case-by-case basis. They would prefer not to have a
list of conditions for which they would be required to report,
but a list of criteria to help clinical decision-making and
prioritising results. Additionally, clinicians in our sample
clearly expressed a preference toward more targeted tests to
avoid the discovery of unrelated findings that would be diffi-
cult to feed back and might be confusing and disorienting for
patients. As other commentators have suggested “[A]n in-
formed, targeted approach to genome analysis makes the
clinical test a more discrete and definable entity that is possi-
ble to interpret and reduces unwanted incidental findings”
(Wright et al. 2013, p. 3). Greek experts seemed to understand
a patient’s autonomy in different ways and, as has been
suggested elsewhere (Ross et al. 2013; Klitzman et al. 2013).
Regarding the disclosure of IFs directly to familymembers,
not through the patient, our experts seemed to be willing to
proceed with caution, especially when IFs were serious. This
“duty to warn family members of inherited health risk” (Offit
et al. 2004) has been discussed elsewhere and health-care
professionals have suggested that they have a responsibility to
encourage but “not to coerce the sharing of genetic informa-
tion in families” (Storm et al. 2008). However, failure to warn
family members about hereditary disease risks has already
resulted in three lawsuits against physicians in the USA (Offit
et al. 2004) while recent changes in Australian law now allow
disclosure to relatives (Otlowski 2013). These changes suggest
that this issue requires further research in order to assist
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clinicians. Legal and professional responsibilities should be
clarified to avoid driving clinicians to over or under investigate
and report because of fear of repercussions (Wright et al. 2013).
Conclusion
Experts from Greece reported the lack of any supportive
mechanisms, even though clinical sequencing is integrated
in the health services available to patients. The availability
and use of sequencing in the clinical setting is expected to
increase, and experts are asking for guidelines to support them
with the return of clinically valid and actionable results.
Further research in Greece is needed to seek the exact type
of guidelines that should be created as well as to investigate
cultural differences between nationalities and cultural and
professional groups in Europe and internationally.
Although our results should be treated with caution due to
the small sample size, we believe we have demonstrated the
current situation regarding clinical sequencing in Greece. The
preparation of guidelines for Greece could follow examples set
in other countries, but there is a clear need to ensure that they
reflect the Greek situation. Country-specific characteristics
should be taken into consideration such as cultural lay beliefs
and a health-care system that is mainly based on professionals’
discretion and willingness to act on patients’ best interest,
despite the lack of any clear support from the system. Such
guidance will allow experts in Greece to continue to provide
excellent and thoughtful care for their patients.
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